MediTox (Czechia)

The effects of live yeast (strain CNCM I-4407; Actisaf Sc 47; Phileo Lesaffre Animal Care, Marcq-en-Baroeul, France) administration on nutrient digestibility and fecal microflora in dogs were investigated. The study included 24 young beagle dogs. They were allocated in control and live yeast (LY) groups (6 males and 6 females in each). During the Adaptation (d 1 to 28) and Trial (d 29 to 70) periods, the dogs received a standard dry pelleted diet. In the Trial period, the LY dogs were given capsuled Actisaf Sc 47 at 1 g/kg live weight with at 2.9 × 10 cfu/g. The control dogs received empty capsules. Live weight and feed consumption were recorded. Blood samples for complete blood count (CBC) and serum biochemistry (urea, creatinine, alkaline phosphatase, and alanine aminotransferase) and fecal samples for pH, microbiology, DM, lactic acid, and ammonia and digestibility evaluation were collected during the Trial period from each dog. The LY dogs had a higher ( < 0.05) weight gain during the Trial period than the control ones. Feed consumption was not adversely affected by LY. The CBC values and urea, creatinine, alkaline phosphatase, and alanine aminotransferase were not adversely affected by LY. Live yeast did not significantly influence pH of fresh feces. Fecal lactic acid and ammonia concentrations were not affected. The LY dogs showed lower ( < 0.05) Escherichia coli and fecal enterococci counts in feces than the control ones. Lactic acid bacteria, Clostridium perfringens, and total coliforms did not show any significant differences between the treatments. The LY dogs showed a higher ( < 0.05) apparent digestibility of NDF. Digestibilities of DM, ash, crude fiber, CP, and fat were not influenced.